Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The ...
Hosted on MSN14m
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue EstimatesAngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback